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Abstract Tonic GABAA receptors are a subpopulation of re-
ceptors that generate long-lasting inhibition and thereby con-
trol network excitability. In recent years, these receptors have
been implicated in various neurological and psychiatric disor-
ders, including Parkinson’s disease, schizophrenia, and epi-
lepsy. Their distinct subunit composition and function, com-
pared to phasic GABAA receptors, opens the possibility to
specifically modulate network properties. In this review, the
role of tonic GABAA receptors in epilepsy and as potential
antiepileptic target will be discussed.
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Abbreviations
AED Antiepileptic drug
CA Cornu ammonis region
DG Hippocampal dentate gyrus
GABARAP γ-Aminobutyric type A receptor-
associated protein
GABAAR γ-Aminobutyric type A receptor
IPSP Inhibitory postsynaptic potential
PSD Postsynaptic density
TLE Temporal lobe epilepsy
Introduction
Worldwide, more than 50 million people are suffering from
epilepsy [1]. Temporal lobe epilepsy (TLE) is the most com-
mon type of partial onset epilepsy [2]. Epilepsy has a severe
impact on patients’ quality of life, first, because patients ex-
perience unpredictable seizures that restrict them in activities
of daily living and second, because patients can suffer from
several neuropsychiatric comorbidities such as depression or
cognitive decline. Current treatment options for epilepsy are
insufficient. Approximately 30% of patients are drug resistant
[3], which is defined as failure to achieve seizure freedom
despite two tolerated, adequately applied antiepileptic drug
(AED) schedules [4]. Furthermore, AEDs can have side ef-
fects, including somnolence, behavioral changes, dizziness,
and weight gain. Therefore, there is an urgent need for more
efficacious AEDs with fewer side effects.
The γ-aminobutyric acid (GABA) type A receptor
(GABAAR) is an important target for AEDs, as it is the most
important inhibitory receptor in the central nervous system
and therefore plays an important role in the development
and maintenance of epilepsy. Upon binding of the neurotrans-
mitter GABA to the ionotropic GABAAR, the receptor opens
allowing chloride and bicarbonate ions to diffuse into the cell.
This results in hyperpolarization and a higher excitation
threshold, i.e., an inhibitory postsynaptic potential (IPSP) [5,
6]. GABAARs mediate two different types of inhibition:
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phasic inhibition characterized by a short-lasting IPSP and
tonic inhibition characterized by persistent, long-lasting
IPSP. GABAARs mediating tonic inhibition are different from
those mediating phasic inhibition. They are located outside the
synapse and hence are referred to as perisynaptic or
extrasynaptic receptors. Moreover, the subunit composition
of tonic GABAARs differs from that of phasic GABAARs.
Due to its long-lasting hyperpolarization, tonic inhibition
can be considered as a constant Bbrake on the system^
counterbalancing excitation [7]. Tonic currents are therefore
involved in a broad array of vital physiological functions, such
as regulating neuronal excitability, network oscillations, syn-
aptic plasticity, neurogenesis, neuronal development, informa-
tion processing, and cognition [5, 8–14]. The importance of
this type of inhibition is further emphasized when realizing
that under physiological conditions, the charge carried by ton-
ic GABA currents is bigger than that of synaptic currents. For
instance, tonic inhibition is responsible for generating 75 % of
the total inhibitory charge received by hippocampal neurons
[15].
Considering the important role of tonic GABA signaling in
regulating network excitability, alterations in tonic signaling
must play a role in epilepsy. The current review discusses
physiological tonic GABA signaling, its role in TLE, and
describes existing and future strategies using tonic currents
as novel targets for antiepileptic treatment.
Physiology of Tonic GABA Signaling
In order to discuss the pathophysiological changes taking
place in epilepsy, it is first necessary to understand the phys-
iological principals governing tonic signaling in the central
nervous system. The following paragraphs will discuss the
molecular composition of GABAARs, determinants influenc-
ing tonic signaling including the role of GABAB receptors
(GABABRs), the specific role of tonic inhibition in interneu-
rons, and clustering of GABAARs.
Subunit Composition of Tonic GABAARs
GABAARs are heteropentamers assembled from α1-6, β1-3,
γ1-3, δ, ε, π, and θ subunits [16, 17]. In theory, these different
subunits can combine into thousands of different GABAARs.
In reality however, GABAARs have preferential configura-
tions, which means that the number of different GABAARs
expressed in vivo is limited. Mostly, two α subunits combine
with two β subunits and either a γ or a δ subunit [18]. Some
subunits are inhomogeneously distributed over the brain [19,
20]. For instance,α5 is predominantly found in the hippocam-
pal dentate gyrus (DG) and cornu ammonis (CA) 1 and 3
region. In contrast, δ and γ subunits are found in the cortex,
hippocampus, thalamus, striatum, and cerebellum. At the
subcellular level, some subunits and subunit combinations
are preferentially expressed at extrasynaptic sites (Table 1).
For instance, α5 subunits and receptors consisting of an α4,
α6, and δ subunit are predominantly expressed at
extrasynaptic sites [21, 22], whereas, γ2 is mostly expressed
at the synaptic site [7, 9, 21, 23–27]. To date, knowledge of the
processes guiding these preferential expression sites is incom-
plete. In general, it is assumed that guidance is driven by the
interaction between subunits, anchoring proteins and the cy-
toskeleton [28].
In addition to a specific distribution, the subunit com-
position of GABAARs also influences the affinity for
GABA. For instance, receptors containing an α3 subunit
have a higher affinity for GABA than α5 containing
GABAARs [29–32]. Similarly, δ subunit containing
GABAARs have a higher affinity than those expressing a
γ subunit. This implicates that extrasynaptic GABAARs
have a higher affinity for GABA than synaptic ones [5,
33]. Finally, the subunit composition can also affect the
kinetic properties of GABAARs, e.g., δ subunit containing
GABAARs desensitizes slower [5].
Activation of Tonic GABAARs
Tonic GABAARs can be activated in several ways
(Fig. 1). First of all, repetitive activation of the presynapse
results in increased levels of GABA in the synaptic cleft.
This is due to insufficient time for clearance by GABA
transporters (GATs). As a consequence, GABA can accu-
mulate in the synaptic cleft. Consequently, GABA dif-
fuses to the extracellular space where it activates
extrasynaptic receptors [21, 34, 35]. The degree and speed
of diffusion are influenced by parameters such as the dis-
tance between the synaptic cleft and receptor, diffusional
barriers, and geometry of the synapse [36].
Second, tonic GABAARs may be activated by GABA that
is released from non-vesicular sources [37, 38]. Extracellular
GABA may come from glial cells or dendrites (for a review,
see Yoon and Lee [39]) [40–44], for instance by GAT reversal
[45–51].
Third, opening of tonic GABAARs can occur spontane-
ously in the absence of synaptic activation and even in the
absence of extracellular GABA [52, 53]. This has been
shown in vitro for β1 subunit containing GABAARs in
the rat [54], the human α1β3ε receptor [55], human
α1β1 and α1β1γ2 receptors [56], and in rat hippocampal
slices [57].
The three proposed mechanisms of tonic GABAAR
activation might be complementary: In case of baseline
network activity, tonic activation may be caused by
non-vesicular sources of extracellular GABA or by
spontaneous opening, while in case of excessive
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network activity, GABA may spill into the extracellular
space.
The magnitude of tonic signaling is influenced by several
factors, such as the amount of ambient GABA and the avail-
ability of receptors. Moreover, neuromodulators can alter ton-
ic GABA signaling. An example of neuromodulators are
neurosteroids, a group of neuromodulators that influences δ
subunit containing tonic GABAARs. Binding of these
neurosteroids increases tonic inhibition. Next to this acute
effect, neurosteroids also cause downregulation of certain sub-
units such as the γ2 and δ subunits in the DG [58].
Consequently, tonic and phasic currents decreased [59].
Table 1 Subunit composition of
extrasynaptic GABAARs depends
on brain region and cell type
GABAAR subunits Structure Cell type
α5βγ Subiculum Pyramidal cells [16]
Interneurons [17]
Hippocampus Granular cells [18]
CA1 Pyramidal cells [7]
α6βδ Cerebellum Granular cells [19–21]
Hippocampus Pyramidal cell [7]
α4βδ Thalamus Relay neuron [22–26]
Hippocampus Granular cells [18, 20, 27, 28]
Frontoparietal cortex Pyramidal cells [29]
α1β2δ Hippocampus (Molecular layer) Interneurons [25]
α3βγ Basolateral amygdala Pyramidal cells [30]
α5β3γ2 Striatum Juvenile D1+/D2+ cells [31, 32]
Fig. 1 Mechanisms modulating the activity of tonic GABAARs. Upon
release into the synaptic cleft, GABA is taken up in glia cells by GABA
transporter (GAT) type 3 and metabolized by GABA transaminase or
taken up presynaptically by GAT-1. Tonic GABAARs can be activated
by four mechanisms: (1) spill of synaptically released GABA into the
extrasynaptic space due to insufficient clearance by GATs, (2) non-
vesicular GABA release by GAT reversal, (3) spontaneous opening in
the absence of extracellular GABA, and (4) GABAB receptor activation
increases tonic GABAAR signaling via an intracellular mechanism
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The mechanisms governing tonic inhibition are summa-
rized and illustrated in Fig. 1.
The Influence of GABAB Receptors on Tonic GABA
Signaling
Metabotropic GABABRs are expressed both, presynaptically
and postsynaptically, and are known to modulate seizure ac-
tivity. At the presynapse, they act as autoreceptors, i.e., acti-
vation of this receptor causes a reduced Ca2+ entry, resulting in
a decreased GABA release. At the postsynaptic site,
GABABRs can modulate tonic signaling. For instance, activa-
tion of GABABRs by baclofen increases the tonic current of δ
containing GABAARs in thalamocortical cells, DG, and cere-
bellar granule cells [60]. The mechanisms by which GABAB
signaling controls tonic GABAAR currents are not fully un-
derstood. It is hypothesized that activation of postsynaptic
GABABRs initiates a G-protein coupled signal transduction
to δ containing GABAARs (for review, see [61]). The contri-
bution of this pathway versus that of autoreceptors in the
proconvulsive or anticonvulsive activity of GABABR-modu-
lating drugs remains to be elucidated.
The spatial expression of GABABRs at the postsyn-
aptic membrane shares striking resemblance with that of
extrasynaptic or perisynaptic GABAARs. Most likely
GABAARs and GABABRs are activated simultaneously
due to spillover of GABA [34, 62, 63]. Furthermore,
GABABRs are found on astrocytes. As these cells have
an essential buffering capacity, glial GABABRs may be
important in regulating the concentration of extracellular
GABA [64, 65].
Clustering and Trafficking of GABAAR
The expression of GABAARs is tightly controlled and de-
pends on assembly, maturation, and recycling of different sub-
units. These processes are regulated by a complex interaction
of various proteins such as GABAAR-associated protein
(GABARAP) and N-ethylmaleimide-sensitive factor (for a
review, see Lorena Arancibia-Cárcamo 2009). Normally,
GABAARs are inserted into the cell membrane at the
extrasynaptic location and diffuse via lateral trafficking into
the postsynaptic density (PSD; Fig. 2). Here, they are clus-
tered by different adhesion and scaffolding proteins, i.e.,
gephryin, dystrophin, and neurexin [66]. GABAARs can also
be clustered at the extrasynaptic site by molecules such as
radixin [67, 68]. Receptors are able to migrate back and forth
between the synaptic and extrasynaptic site [69, 70] and can
rapidly cycle back after endocytosis to the extrasynaptic mem-
brane [28]. It is unclear which mechanisms cause receptors to
diffuse away from the synaptic site or facilitate their entry into
the PSD.
An increase in extrasynaptic clustering influences tonic
signaling. Surprisingly, not only the amount of channels but
also individual channel properties change with increased clus-
tering [71, 72]. Clustered GABAARs have a higher EC50,
deactivate faster, and desensitize slower compared to diffuse
receptors [72]. The heterogeneity of receptors and preference
of certain subunits to cluster extrasynaptically complicate the
understanding of this mechanism [71].
Tonic Inhibition in Interneurons
The activity of interneurons paces the hippocampal rhythm.
This rhythmogenesis is therefore partly controlled by the tonic
GABA conductance in interneurons. This is demonstrated by
the finding that δ subunit knockoutmice show higher frequency
γ oscillations [11]. However, interneurons show a bivalent re-
sponse to ambient GABA. At low levels of GABA, tonic inhi-
bition is reduced, causing an enhanced excitability of interneu-
rons [24, 73] and consequently an increased inhibition of pyra-
midal cells. Moreover, this weak tonic conductance imposes
regular firing of interneurons that synchronizes the CA 3 net-
work [74]. On the other hand, high concentrations of ambient
GABA inhibit interneurons [75]. As a result, they become less
excitable and thus release their brake on pyramidal cells.
However, under these high extracellular GABA levels, the py-
ramidal cells themselves also receive more tonic inhibition.
This inhibition can counterbalance the loss of interneuronal
inhibition. Thus, control of the extracellular GABA concentra-
tion provides both a direct and indirect mechanism to regulate
pyramidal cell activity [73].
Tonic GABA Signaling in Temporal Lobe Epilepsy
Considering the important role of tonic GABA signaling in
regulating network excitability, it is likely that tonic GABA
signaling is altered in the occurrence of seizures or in the
development of a seizure prone network (epileptogenesis)
[76, 77]. Studies on tonic GABA signaling in epilepsy will
be discussed in the following paragraph and are summarized
in Table 2.
Single nucleotide polymorphisms and mutations in genes
coding for tonic subunits are associated with several types of
epilepsy [78–80]. For instance, Dibbens et al. [78] and Feng
et al. [81] showed that genetic alterations in the GABRD gene,
that codes for the tonic δ subunit, cause a decrease in tonic
inhibition in complex idiopathic generalized epilepsies.
Eugene et al. [80] found that in human epileptic syndromes
with febrile seizures, mutations in the γ subunit cause a de-
crease in tonic currents by reducing the surface expression of
α5 containing GABAARs.
Results on the expression levels of tonic subunits in exper-
imental epilepsy are contradictory (for a full overview, see
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Table 2). Whereas several studies showed an increase of the
α5 subunit [82–84] particularly in the DG in the kainate and
pilocarpine model, others showed a decrease in CA1 in the
pilocarpine model [84], in the DG in the kainate model [85] in
CA1, CA2, and CA3 in the pilocarpine model [83], and in the
DG, CA1, and CA3 in the hippocampal kindling model and
the pilocarpine model [86–88]. The total and surface expres-
sion of the δ subunit in the DG of the hippocampus decreases
after status epilepticus, both during the latent phase shortly
after the induction of a status epilepticus and during the chron-
ic phase, when animals experience spontaneous recurrent sei-
zures [89–91]. As the expression of the δ subunit is concom-
itantly increased in the microsomal fraction, these re-
sults suggest that these subunits do not reach the cell
membrane and are retained in the endoplasmatic reticiulum.
All together, is seems that there is a quantitative decrease in
the amount of tonic subunit expression at the messenger RNA
(mRNA) and protein level in different hippocampal regions
acutely after an epileptogenic insult but also during the chron-
ic phase.
Nonetheless, electrophysiological studies have shown that
alteration in the expression of tonic subunits is not accompa-
nied by a functional loss of tonic inhibition [89, 91–93]. Some
studies even report an increase of tonic signaling in experi-
mental epilepsy shortly after status epilepticus and during the
epileptogenic phase in the pilocarpine model [88, 94]. If, as
animal studies suggest, subunits providing tonic currents are
downregulated and tonic inhibition is unchanged or increased,
then tonic GABA currents must be maintained by other
means.What factors are possibly involved in maintaining ton-
ic currents?
As the amplitude of tonic GABA signaling is determined
by the concentration of GABA in the synaptic cleft, an in-
creased GABA concentration could compensate for a decrease
in the quantity of tonic receptor subunits. As discussed before,
increased extracellular GABA concentrations can result from
a reduced activity or number of GATs. Indeed, GAT-1, which
is expressed presynaptically, was shown to be upregulated in
the molecular layer of the hippocampus acutely after experi-
mental status epilepticus, in the chronic phase in the kainic
acid model [95] and in hippocampal specimen from patients
with temporal lobe epilepsy [96]. Andre et al. [97] have shown
that GAT-1 alterations depend on the time point in the epilep-
togenic process and the region investigated. Whereas GAT-1
was upregulated in the inner molecular layer of the hippocam-
pus, it was downregulated in CA1 in rats with spontaneous,
recurrent seizures compared to controls. Another important
regulator of extracellular GABA is GAT-3, which is located
on glial processes. The expression of both GAT-1 and GAT-3
are altered in hippocampi from TLE patients. As these chang-
es vary per hippocampal subregion and GATs can reverse,
causing non-vesicular GABA release, it is difficult to predict
Fig. 2 Receptor trafficking to the
membrane and between the
extrasynaptic and synaptic site.
Additionally, examples of
extrasynaptic and synaptic
anchoring proteins are shown
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the effect of these alterations to hippocampal physiology [63,
95].
Whether an actual functional reversal of transporters occurs
in epilepsy is difficult to establish due to the technical restric-
tions of measuring intracellular GABA concentrations. GAT
reversal is eventually favored by an increased rate of GABA
synthesis by GAD [95] that in its turn can be caused by an
increase in metabolic rate of neurons as seen in epilepsy.
Another possibility of increasing extracellular GABA is by
increased activity of glutamic acid decarboxylase (GAD),
the enzyme responsible for GABA synthesis. Esclapez and
Houser [98] have shown that GAD 65 and 67 are increased
in animals with spontaneous, recurrent epileptic activity at the
mRNA and protein level. Acutely after status epilepticus,
GAD 65 and 67 expression decreased in the hippocampal
hilus, whereas GAD 67 expression in the DG is increased
[99]. In the chronic phase, GAD accumulated in interneurons
of the DG [82, 100]. Interestingly, GAD 65 null mice show
spontaneous seizures [101].
Additionally, different channels (e.g., two-pore domain
potassium channels) and receptors or GABAARs with a
different subunit composition could take over tonic func-
tion [74, 102]. Indeed, pharmacological experiments dem-
onstrated that increased tonic GABA currents are not me-
diated by α5- but δ-containing GABAARs in epilepsy
[88]. In several studies, it has been shown that the down-
regulation of δ subunits in the DG is accompanied with an
increase in the expression of receptors containing the α4
and γ2 subunits [86, 89, 90, 103]. As mentioned before,
these receptors have a lower affinity for GABA, which
implies that tonic GABA currents can only be maintained
if there is an increase in extracellular GABA. Possibly,
receptors that are typically expressed synaptically under
physiological conditions are increasing shifted toward the
extrasynaptic site in epilepsy. Evidence for this process
comes from the shift of the γ2 subunit that is increasingly
expressed at the extrasynaptic site in a murine model of
epilepsy [104]. Additional electrophysiological studies are
necessary to fully understand the functional consequences
of quantitative changes in GABAARs.
Toward Antiepileptic Drugs that Target Tonic
GABA Signaling
Considering that tonic currents are functionally pre-
served in epilepsy, they constitute a potential treatment
target [5, 15]. In order to increase tonic currents, there
are two strategies: increasing the extracellular concentra-
tion of GABA or agonizing GABAARs by ligands bind-
ing to tonic subunits. In Fig. 1, the mechanisms modu-
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will be discussed in the light of increasing tonic inhibi-
tion in the next paragraph.
Increasing the Extracellular GABA Concentration
Extracellular GABA concentrations are controlled by synthe-
sis, breakdown, and clearance from the synaptic cleft. The
synthesis of GABA in the presynaptic terminal is determined
by the activity of GAD 65, and the activity of single GAD is
influenced by processes such as phosphorylation and the pres-
ence of co-factors such as pyridoxal 5′-phosphate. GAD con-
centrations can be increased by enhancing its transcription by
stimulating promoter activity or by influencing epigenetic
mechanisms that lead to a higher transcription rate [89, 105].
Alternatively, GAD can be potentiated by viral vector-
mediated targeted delivery of therapeutic GAD. This strategy
has already proven to be successful in experimental and clin-
ical studies for Parkinson’s disease [106–108]. An advantage
of viral vector-mediated targeted delivery therapy is its spatial
specificity that potentially eliminates site effects caused by
unspecific targeting.
Alternatively, a higher release of GABA could be achieved
by increasing the concentration of GABA in individual pre-
synaptic vesicles. GABA is packed into vesicles by vesicular
neurotransmitter transporters (VGAT), and their activity de-
pends on electrochemical components. Boosting vesicular
GABA transport might be achieved by pharmacologically in-
creasing the activity of VGAT or by increasing its gene
expression.
A second mechanism to increase extracellular GABA con-
centrations is inhibiting breakdown of GABA that is mediated
by GABA transaminase (GABA-T). The second-line AED
vigabatrin works via irreversibly inhibiting GABA-T [109,
110], increasing the concentration GABA in the synaptic cleft
[111]. Furthermore, there is evidence that vigabatrin increases
GABA release and constrains glial GABA uptake [112, 113].
Other more potent and novel inhibitors of GABA-T are
ethanolamine-O-sulfate (EOS), L-cycloserine, and
phenylethylidenehydrazine. Interestingly, the latter is used in
various psychiatric disorders and increase extracellular
GABA concentrations in vivo and decrease epileptiform ac-
tivity in the rat ex vivo [114]. However, its anticonvulsant
properties in vivo varied depending on the seizure model used.
Several other GABA-T inhibitors such as gabaculine, gamma-
acetylenic GABA, and gamma-vinyl GABA do not appear
suitable for treatment of convulsive disorders in humans due
to their severe and sometimes lethal side effects [115].
The last mechanism to increase extracellular GABA con-
centrations is by decreasing GABA clearance from the synap-
tic cleft by influencing GAT. Two drugs acting at GATs are
SNAP-5114 and tiagabine that inhibit GAT-2 and -3, and
GAT-1, respectively [116]. Indeed, they increase the concen-
tration of extracellular GABA in vivo [117]. Tiagabine seems
to be efficient as an add-on treatment in partial and secondarily
generalized seizures, reducing seizure frequency [118].
However, clinical data show disappointing results with pa-
tients suffering from paradoxical proconvulsive effects
[119]. So far, no pharmaceutical interventions exits that acts
by reversing GATs.
Extrasynaptic GABAAR Agonists
In addition to enhancing extracellular GABA, enhancement of
tonic GABAARs can also be achieved by using specific ago-
nists. Ganaxolone is a neurosteroid and a tonic GABAAR
agonist, binding to and influencing the δ subunit. At low con-
centrations, it potentiates GABAARs (positive allosteric mod-
ulator), while at higher doses, it acts by directly binding to the
δ subunit. Several studies using ganaxolone show promising
results, both in rodent seizure models [120–122] as well as in
clinical studies [123]. In patients with infantile spasms, seizure
frequency was decreased by at least 50 % in one third of the
patients [124]. The frequency of occurrence and type of side
effects were comparable to classic antiepileptic drugs.
Currently, ganoxalone is investigated as an adjunctive treat-
ment in patients with drug-resistant, partial onset seizures (tri-
al identifier NCT01963208).
Also, the anesthetic 4,5,6,7-tetrahydroisoxazolo(5,4-
c)pyridin-3-ol (THIP, gaboxadol) agonizes the δ subunit.
THIP can reduce spikes in vitro and in vivo [125, 126]. In a
clinical study with a small sample size, a trend toward seizure
reduction was demonstrated [127]. However, there is conflict-
ing evidence showing no effect on epileptiform activity [128,
129]. Other anesthetics, which selectively target the δ subunit
are alphaxalone and propofol. Due to its anesthetic effects,
these drugs are not suitable for the treatment of epilepsy.
A relatively new compound binding selectively to the δ
subunit is the GABA agonist DS-1 and an enhancer DS-2.
DS-2 has been shown to increase tonic currents in the thalamic
neurons in vitro [130].
Challenges of Enhancing Tonic Signaling
The development of AEDs aimed at tonic receptors is not
straightforward due to several reasons. First of all, the long-
term use of tonic GABAAR agonists, in particular
neurosteroids, can lead to a downregulation of α4 and δ sub-
units. The elimination of the binding site by downregulation
ceases the potential long-term benefits of this strategy.
Furthermore, AEDs can have side effects. Side effects depend
on the concentration of the compound and the distribution in
the central nervous system. However, one advantage of
extrasynaptic GABAARs is their cell type and brain region-
specific subunit composition. The advantage of this heteroge-
neity of receptors is that all subunits differ in their affinity for
agonists and antagonists. The aspecificity of drugs can
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therefore be partially overcome by using different dosages of
AEDs. For instance, δ subunit containing receptors have the
highest affinity for GABA.
Furthermore, compensatory alterations in other cells or
brain regions could be a cause of ineffectiveness of AEDs.
For instance, increasing GABA concentrations through
inhibition of GAT-3 is not effective in the hippocampus
due to the compensatory action of GAT-1. In the thala-
mus, however, GAT-3 inhibition increases tonic signal-
ing. Related to these region-specific effects is the fact
that certain types of epilepsy appear to be more suitable
targets for tonic GABA modulation. For instance, in the
absence of seizures, tonic inhibition in the thalamus is upreg-
ulated rather than downregulated [76]. Enhancing tonic sig-
naling triggers slow wave discharges—a hallmark of this type
of epilepsy—and consequently aggravates seizures [131]. In
this light, it becomes plausible that an increase in tonic inhi-
bition particularly in the thalamus causes absence-like side
effects.
It is important to realize that an increase in extracellular
GABA has consequences for synaptic receptors and receptors
on which GABA acts as a (partial) ligand (i.e., GABABRs). In
this regard, it might be sometimes difficult to disentangle
whether the specific increase in tonic currents or a gross en-
hancement in the inhibitory tone causes antiepileptiform
effects.
Future Directions for the Development of Tonic AEDs
To overcome the challenges described above, it is necessary to
reveal the complex network effects of tonic signaling
and develop more specific and targeted drugs. By
targeting specific subunits, one could make use of the
particular pharmacokinetic properties such as affinity,
channel opening time, refractory period, etc., which would
allow fine-tuning of neuronal activity in the presence of
varying concentrations of antagonist or agonists [23, 24,
88, 132].
Potential new specific strategies are evolving. An example
of a cell-type specific therapy is optogenetics [133]. With
optogenetics, certain genetically manipulated neurons are
inhibited or excited by light. If one succeeds in selectively
inhibiting the principal neuron only in the epileptogenic zone
or increasing the activity of interneurons, this would potential-
ly create new treatment opportunities. In the case of epilepsy,
it could be beneficial to increase the release of GABA and
therefore increase ambient GABA concentrations, which, in
turn, can activate extrasynaptic receptors. Considering the im-
portant buffering capacity of astroglia cells, those might also
form an attractive target with regard to regulating the concen-
tration of extracellular GABA.
Additionally, by using cell-specific approaches, side effects
could be limited. Also, designer receptors exclusively
activated by designer drugs (DREADDs) might evolve as fu-
ture treatment strategy [134]. With DREADDs, receptors are
administered to the central nervous system via a viral vector
into specific cell types. A specific oral drug activates these
receptors. In fact, in epilepsy, there are two options with re-
gard to DREADDs [135]. On one hand, inserting the receptor
into the presynaptic gabaergic terminal and activating it
by the oral drug could increase presynaptic GABA release and
therefore augment not only tonic but also phasic inhibition.
On the other hand, the precise activation of certain interneuron
populations in the epileptogenic zone might contribute to a
higher excitation threshold of the principal neuron, which, in
turn, might be beneficial at the network level. The advantage
of this procedure is the specificity of the treatment and fact that
it is less invasive compared to optogenetic techniques.
Another strategy might be to interfere with receptor traf-
ficking. A potential approach would be to enhance tonic sig-
naling by increasing receptor expression and anchoring.
This could be achieved by stimulating de novo synthe-
sis or by promoting the migration of receptors from the
synaptic to the extrasynaptic site. A potential conse-
quence might be the loss of synaptic receptors, which,
in turn, leads to the loss of phasic inhibition, which is
detrimental to epilepsy. Next to increasing de novo syn-
thesis, shuttling of ready-made receptors to the cell sur-
face could be enhanced.
Lastly, it might be desirable to improve anchoring at the
extrasynaptic side. In this regard, anchoring proteins such as
radixin might play a crucial role. Whereas disrupting certain
protein-protein interactions becomes more feasible by using
virus-derived proteins [136, 137], enhancing these interac-
tions is more difficult.
Conclusion
Tonic inhibition is maintained in epilepsy and therefore serves
as an attractive substrate for interventions. Drugs aimed at
tonic GABA signaling, such as ganoxalone, show promising
anticonvulsive results in rodent studies, but they trigger side
effects as well. Future detailed knowledge about receptor traf-
ficking and particular changes in specific brain regions will
contribute to more rational drug design leading to more potent
drugs with fewer side effects.
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